Drugs / anti-ILT3 CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04803929 | Mar 2021 → Mar 2024 | acute monocytic leukemia, acute myelomonocytic leukemia M4 | Carbiogene Therapeutics Co. Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-ILT3 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04803929 ↗ |
| Modality | Cell therapy | “novel anti-ILT3 CAR-T cell therapy” NCT04803929 ↗ |
| Route | Intravenous | “intravenously adminstered with anti-ILT3 CAR-T cells” NCT04803929 ↗ |